4.8 Article

Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-up Study

期刊

GASTROENTEROLOGY
卷 139, 期 2, 页码 474-482

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2010.04.048

关键词

Spontaneous HBsAg Seroclearance; Incidence; Determinants

资金

  1. Department of Health, Executive Yuan, Taipei, Taiwan
  2. Academia Sinica, Taipei, Taiwan
  3. National Health Research Institutes, Chunan, Taiwan
  4. Bristol-Myers Squibb Company, Wallingford, CT

向作者/读者索取更多资源

BACKGROUND & AIMS: Seroclearance of hepatitis B surface antigen (HBsAg) is one of the most important clinical outcomes for chronic hepatitis B treatment trials. Few studies have explored the incidence and determinants of spontaneous seroclearance using a long-term follow-up study. This study aimed to examine the natural history and predictors of HBsAg seroclearance. METHODS: A total of 3087 individuals with chronic hepatitis B virus infection were enrolled between 1991 and 1992 in this community-based study. Serum samples collected at baseline and follow-up examinations were tested for HBsAg, hepatitis B e antigen (HBeAg), serum hepatitis B virus (HBV)-DNA levels, and anti-hepatitis C virus serostatus. Cox proportional hazards models were used to estimate HBsAg seroclearance rate ratios associated with various determinants. RESULTS: HBsAg seroclearance occurred in 562 participants during 24,829 person-years of follow-up evaluation, giving a 2.26% annual seroclearance rate. HBV-DNA levels at baseline and follow-up evaluation were the most significant predictor of seroclearance. Higher HBV viral loads conferred lower HBsAg seroclearance rates (P < .001). A spontaneous decrease in follow-up HBV-DNA level (>= 3 log) was associated significantly with seroclearance, showing an adjusted odds ratio of 4.17 (95% confidence interval, 2.55-6.82). Among those with seroclearance, 95.8% had undetectable HBV-DNA levels before seroclearance. Cumulative incidence of HBsAg seroclearance at 60 and 100 months after serum HBV-DNA level decreased to undetectable was 25.8% and 51.3%, respectively. CONCLUSIONS: This study reveals determinants of HBsAg seroclearance, and suggests that a low viral load is an important factor affecting the natural seroclearance of HBsAg, indicating significant clinical implications for the treatment of chronic HBV.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

The case for simplifying and using absolute targets for viral hepatitis elimination goals

Homie Razavi, Sarah Blach, Devin Razavi-Shearers, Faisal Abaalkhail, Zaigham Abbas, Ayat Abdallah, Paulo Abrao Ferreira, Laith Jamal Abu Raddad, Danjuma Adda, Kosh Agarwal, Alessio Aghemo, Aijaz Ahmed, Said A. Al-Busafi, Waleed Al-hamoudi, Saad Al-Kaabi, Hamad Al-Romaihi, Badr Aljarallah, Khalid AlNaamani, Saleh Alqahtani, Khalid Alswat, Ibrahim Altraif, Tarik Asselah, Bruce Bacon, Fernando Bessone, Abdul Rahman Bizri, Tim Block, Ferruccio Bonino, Carlos Eduardo BranclaoMello, Kimberly Browny, Philip Bruggmann, Maurizia Rossana Brunetto, Maria Buti, Joaquin Cabezas, Jose Luis Calleja, Erika Castro Batanjer, Henry Lik-Yuen Chan, Henry Chang, Chien-Jen Chen, Peer Brehm Christensen, Wan-Long Chuang, Laura Cisneros, Chari Cohen, Massimo Colombo, Brian Conway, Curtis Cooper, Antonio Craxi, Javier Crespo, Esther Croes, Donna Cryer, Fernando Passos Cupertino de Barros, Moutaz Derbala, John Dillon, Wahid Doss, Xiaoguang Dou, Joseph Doyle, Ann-Sofi Duberg, Ellen Dugan, Rick Dunn, Geoffrey Dusheiko, Hisham El Khayat, Manal H. EI-Sayed, Ahad Eshraghian, Gamal Esmat, Rafael Esteban Mur, Sameera Ezzat, Karolin Falconer, Eduardo Fassio, Paulo Ferrinho, Steven Flamm, Robert Flisiak, Graham Foster, James Fung, Javier Garcia-Samaniego, Robert G. Gish, Fernando Goncales, Waldemar Halota, Waseem Hamoudi, Mohamed Hassany, Angelos Hatzakis, Susan Hay, Sayed Himatt, I. M. Hoepelman, Yao-Chun Hsu, Yee Tak Hui, Bela Hunyady, Ira Jacobson, Naveed Janjua, Harry Janssen, Peter Jarcuska, Kenneth Kabagambe, Tatsuya Kanto, Jia-Horng Kao, Sabahattin Kaymakoglu, David Kershenobich, Faryal Khamis, Dong Joon Kim, Young Kim, Loreta A. Kondili, Shyamasundaran KottiliI, Anna Kramvis, Marcelo Kugelmas, Masayuki Kurosaki, Karine Lacombe, Martin Lagging, WaiCheung Lao, Daniel Lavanchy, Jeffrey Lazarus, Alice Lee, Samual S. Lee, Miriam Levyl, Valentina Liakina, YoungSuk Lim, Shuang Liu, Willis Maddrey, Reza Malekzade, Rui Tato Marinho, Poonam Mathur, Mojca Maticic, Maria Cassia Mendes Correa, Jorge Mera, Shahin Merat, Sherif Mogawer, Rosmawati Mohamed, Beat Muellhaupti, David Muljono, Ibrahim Mostafa, Mendez Sanchez Nahum, Arif Nawaz, Francesco Negro, Michael Ninburg, Qing Ning, Boatemaa Ntiri-Reid, Pagbajabyn Nymadawa, Anne Oevrehus, Necati Ormeci, Mauricio Orrego, Alaa Osman, Tsendsuren Oyunsuren, Calvin Pant, Vassiliki Papaevangelou, George Papatheodoridis, Stephanie Popping, Papu Prasad, Rittoo Prithiviputh, Huma Qureshi, Alnoor Ramji, Kathryn Razavi-Shearer, Rajender Reddy, William Remak, Clemens Richter, Ezequiel Ridruejo, Geert Robaeys, Stuart Robert, Lewis Roberts, Francoise Roudot-Thoraval, Sammy Saab, Sanaa Said, Amjad Salamat, Faisal Sanai, Juan Francisco Sanchez-Avila, Eugene Schiff, Raymond Schinazi, Giada Sebastiani, Carole Seguin-Devaux, R. P. Shanmugam, Ala Sharara, Sonjelle Shilton, Daniel Shouval, William Sievert, Marieta Simonova, Amir Ali Sohrabpour, Mark Sonderup, Alejandro Soza, C. Wendy Spearman, Nancy Steinfurth, Mark Sulkowski, Soek-Siam Tan, Junko Tanaka, Dhondup Tashi, Hla-Hla Thein, Peyton Thompson, Ieva Tolmane, Mehlika Toy, Jonas Valantinas, David Van de Vijver, Patricia Velez-Moller, Adriana Vince, Imam Waked, Su Wang, Heiner Wedemeyer, Vincent Wong, Qing Xie, Seiji Yamada, Hwai- Yang, Kakharman Yesmembetov, Yusuf Yilmaz, Zobair Younossi, Ming-Lung Yu, Man-Fung Yuen, Cihan Yurdaydin, Aasim Yusuf, Amany Zekry, Stefan Zeuzem

Summary: The 69th World Health Assembly endorsed the goal to eliminate hepatitis infection as a public health threat by 2030, followed by global targets for the care and management of hepatitis B and hepatitis C infections. However, tracking countries' progress towards these elimination goals revealed limitations of existing targets and recommended changes to simplify and adjust the targets for better impact and recognition of countries' efforts.

JOURNAL OF VIRAL HEPATITIS (2021)

Article Gastroenterology & Hepatology

Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine

Jiyoon Park, An K. Le, Tai-Chung Tseng, Ming-Lun Yeh, Dae Won Jun, Huy Trinh, Grace L. H. Wong, Chien-Hung Chen, Cheng-Yuan Peng, Sung Eun Kim, Hyunwoo Oh, Min-Sun Kwak, Ka Shing Cheung, Hidenori Toyoda, Yao-Chun Hsu, Jae Yoon Jeong, Eileen L. Yoon, Teerapat Ungtrakul, Jian Zhang, Qing Xie, Sang Bong Ahn, Masaru Enomoto, Jae-Jun Shim, Chris Cunningham, Soung Won Jeong, Yong Kyun Cho, Eiichi Ogawa, Rui Huang, Dong-Hyun Lee, Hirokazu Takahashi, Pei-Chien Tsai, Chung-Feng Huang, Chia-Yen Dai, Cheng-Hao Tseng, Satoshi Yasuda, Ritsuzo Kozuka, Jiayi Li, Christopher Wong, Clifford C. Wong, Changqing Zhao, Joseph Hoang, Yuichiro Eguchi, Chao Wu, Yasuhito Tanaka, Ed Gane, Tawesak Tanwandee, Ramsey Cheung, Man-Fung Yuen, Hyo-Suk Lee, Ming-Lung Yu, Jia-Horng Kao, Hwai-I Yang, Mindie H. Nguyen

Summary: This study aimed to determine the rates of cirrhosis and hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB), stratified by age, sex, treatment status, and disease activity. The results show that there is significant variability in CHB disease progression rates even among lower-risk populations.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B

Hui-Han Hu, Wen-Juei Jeng, Mei-Hung Pan, Wun-Sheng Luo, Chia-Ling Chang, Yen-Tsung Huang, Chien-Yu Su, Chen-Tse Chiang, Chin-Lan Jen, Yu-Chuan Chien, Shen-Nan Lu, Li-Yu Wang, Li-Rung Huang, Mei-Hsuan Lee, Jessica Liu, Mindie H. Nguyen, Chien-Jen Chen, Hwai- Yang

Summary: sPD-1 level is a novel marker that predicts spontaneous HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B with undetectable HBV DNA.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Public, Environmental & Occupational Health

G-Computation to Causal Mediation Analysis With Sequential Multiple Mediators-Investigating the Vulnerable Time Window of HBV Activity for the Mechanism of HCV Induced Hepatocellular Carcinoma

An-Shun Tai, Yen-Tsung Huang, Hwai- Yang, Lauren V. Lan, Sheng-Hsuan Lin

Summary: Regression-based approaches are commonly used in causal mediation analysis, but they may not be efficient in cases with multiple mediators. Therefore, a flexible simulation-based approach was developed to address estimation issues and increase flexibility in model selection. The method was evaluated using a Taiwanese Cohort Study dataset and showed promising results in investigating the mediating role of HBV viral load in the effect of HCV infection on hepatocellular carcinoma.

FRONTIERS IN PUBLIC HEALTH (2022)

Letter Gastroenterology & Hepatology

Letter: sPD-1 as a predictor for HBsAg seroclearance-shed light on inactive carriers with chronic hepatitis B. Authors' reply

Wen-Juei Jeng, Mei-Hung Pan, Hwai- Yang

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Gastroenterology & Hepatology

Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B

Yu-Ju Chu, Wen-Juei Jeng, Mei-Hung Pan, Hui-Han Hu, Wen-Sheng Luo, Chien-Yu Su, Chen-Tse Chiang, Chin-Lan Jen, Chien-Jen Chen, Hwai- Yang

Summary: Serum sPD-1 levels may serve as a novel immunological predictor for spontaneous HBeAg seroclearance in patients with chronic hepatitis B. Lower baseline sPD-1 levels and long-term decline in sPD-1 levels were independent predictors for HBeAg seroclearance, particularly significant in patients with genotype C infection.

JOURNAL OF GASTROENTEROLOGY (2022)

Article Virology

The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays

Wen-Juei Jeng, Chien-Hung Chen, Yi-Wen Wang, Mei-Hung Pan, Chia-Wei Lin, Chun-Yen Lin, Hwai- Yang

Summary: There is no correlation between sPD-1 levels measured by MyBioSource (MB) and R&D (RD) kits. The sPD-1 measured by MB showed strong correlations with HBsAg, HBV DNA, and ALT levels, while an opposite trend was seen with the RD kit. Multivariate linear regression analysis indicated that HBsAg and ALT levels were the major factors associated with sPD-1 levels measured by MB and RD, respectively.

VIROLOGY JOURNAL (2022)

Article Gastroenterology & Hepatology

Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints

Shanshan Wu, Jialing Zhou, Xiaoning Wu, Yameng Sun, Bingqiong Wang, Yuanyuan Kong, Siyan Zhan, Jidong Jia, Hwai- Yang, Hong You

Summary: This study assessed the comparative performance of 14 hepatocellular carcinoma prediction models in chronic hepatitis B patients and found that several models performed best when using on-treatment values within the first 2 years.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

Article Gastroenterology & Hepatology

Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV

Yi-Chung Hsieh, Mei-Hung Pan, Wen-Juei Jeng, Hui-Han Hu, Jessica Liu, Masashi Mizokami, Chien-Jen Chen, Hwai- Yang

Summary: The study found an association between hepatitis B core-related antigen (HBcrAg) and hepatocellular carcinoma (HCC) in chronic hepatitis B patients. The relationship between HBcrAg and HCC was also investigated in individuals seronegative for hepatitis B surface antigen and anti-hepatitis C virus (NBNC) in Taiwan. The results showed that HBcrAg positivity was significantly associated with higher risk of HCC, indicating that it might serve as a marker for identifying individuals at a higher risk of HCC in hepatitis B virus endemic areas.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study

Chien-Wei Peng, Wen-Juei Jeng, Hwai- Yang, Yen-Chun Liu, Rong-Nan Chien, Yun-Fan Liaw

Summary: In HBeAg negative chronic hepatitis B (CHB) patients, stopping tenofovir and other nucleos(t)ide analogues (Nucs) is associated with more frequent and severe clinical relapse. This study found that switching to entecavir more than 12 weeks prior to stopping treatment can delay and reduce the occurrence of clinical relapse and flares.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Oncology

Association between Immunologic Markers and Cirrhosis in Individuals from a Prospective Chronic Hepatitis C Cohort

Ilona Argirion, Jalen Brown, Sarah Jackson, Ruth M. Pfeiffer, Tram Kim Lam, Thomas R. O'Brien, Kelly J. Yu, Katherine A. McGlynn, Jessica L. Petrick, Ligia A. Pinto, Chien-Jen Chen, Allan Hildesheim, Hwai- Yang, Mei-Hsuan Lee, Jill Koshiol

Summary: This study investigated the role of circulating immunologic markers in predicting the progression of liver disease in individuals chronically infected with hepatitis C virus (HCV). The findings suggest that these markers play an important role in predicting HCV-related cirrhosis even 11 years after enrollment.

CANCERS (2022)

Meeting Abstract Gastroenterology & Hepatology

Hepatocellular carcinoma incidence is reduced in cirrhotic chronic hepatitis B patients with HBsAg seroclearance comparing to those with viral suppression

Rachel Wen-Juei Jeng, Chien-Hung Chen, Hwai-I Yang, Yi-Cheng Chen, Yen-Chun Liu, Chia-Ying Wu, Rong-Nan Chien, Yun-Fan Liaw

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Serum soluble programcell death-1 is predictive of hepatocellular carcinoma in untreated chronic hepatitis B patients

Rachel Wen-Juei Jeng, Yu-Ju Chu, Mei-Hung Pan, Hui-Han Hu, Wun-Sheng Luo, Chien-Yu Su, Chen-Tse Chiang, Chin-Lan Jen, Sheng-Nan Lu, Li-Yu Wang, Chien-Jen Chen, Hwai-I Yang

JOURNAL OF HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection

Hui-Chen Wu, Wen-Juei Jeng, Mei-Hung Pan, Yi-Chung Hsieh, Sheng-Nan Lu, Chien-Jen Chen, Hwai- Yang

Summary: This study examined the cumulative risk of hepatocellular carcinoma (HCC) and mortality from liver-related disease among a non-hepatitis virus-infected population. It found that modifiable risk factors such as alcohol consumption, heart disease, diabetes, and abnormal liver function tests were strongly associated with an increased risk of HCC and mortality.

JHEP REPORTS (2022)

Article Medicine, Research & Experimental

SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection

Tsung-Yu Tsai, Ming-Ting Huang, Pei-Shan Sung, Cheng-Yuan Peng, Mi-Hua Tao, Hwai-I Yang, Wei-Chiao Chang, An-Suei Yang, Chung-Ming Yu, Ya-Ping Lin, Ching-Yu Bau, Chih-Jen Huang, Mei-Hung Pan, Chung-Yi Wu, Chwan-Deng Hsiao, Yi-Hung Yeh, Shiteng Duan, James C. Paulson, Shie-Liang Hsieh

Summary: Chronic hepatitis B infection is difficult to eliminate with current antiviral medications. Research shows that a specific antigen in HBV can induce immunosuppression by binding to SIGLEC-3, and certain genetic variations may increase the risk of hepatocellular carcinoma in CHB patients. Blocking SIGLEC-3 could potentially reactivate host immunity to HBV and reduce the incidence of HCC in this patient population.

JOURNAL OF CLINICAL INVESTIGATION (2021)

暂无数据